Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan 30:12:20.
doi: 10.4103/abr.abr_148_21. eCollection 2023.

Nonsteroidal Anti-Inflammatory Drugs in Viral Infections Disease, Specially COVID-19

Narges Chamkouri  1 , Forouzan Absalan  1 , Zahra Koolivand  1 , Mahsa Yousefi  1
Affiliations
Review

Nonsteroidal Anti-Inflammatory Drugs in Viral Infections Disease, Specially COVID-19

Narges Chamkouri et al. Adv Biomed Res. .

Abstract

During the current SARS-CoV-2 (COVID-19) pandemic, some reports were presented based on those nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids may exacerbate symptoms in COVID-19 patients. According to this, we aimed to collate information available in published articles to identify any evidence behind these statements with the aim of helping clinicians on how best to treat patients. We could not find published conclusive evidence for or against the use of NSAIDs in COVID-19 patients. Meanwhile, there appeared to be some evidence that corticosteroids may be beneficial if utilized in the early acute phase of infection, however, conflicting WHO (World Health Organization) evidence surrounding corticosteroid use in certain viral infections means this evidence is not conclusive. Given the current availability of literature, caution should be exercised until further evidence emerges surrounding the use of NSAIDs and corticosteroids in COVID-19 patients. However, the availability of reliable information for clinicians and patients is paramount.

Keywords: COVID-19; Corticosteroid; SARS-CoV-2; nonsteroidal anti-inflammatory drugs.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

References

    1. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020;109:102433. - PMC - PubMed
    1. Bedford J, Enria D, Giesecke J, Heymann DL, Ihekweazu C, Kobinger G, et al. COVID-19: Towards controlling of a pandemic. Lancet. 2020;395:1015–8. - PMC - PubMed
    1. Hui DS, Azhar EI, Madani TA, Ntoumi F, Kock R, Dar O, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health – The latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis. 2020;91:264–6. - PMC - PubMed
    1. McKeever A. Here's what coronavirus does to the body. In: National Geographic. United States: National Geographic Partners, LLC; 2020. [Lat accessed on 2021 Mar 25]. Available from: http://www.nationalgeographic.com/science .
    1. Jarcho JA, Ingelfinger JR, Hamel MB, D’Agostino RB, Sr, Harrington DP. Inhibitors of the renin-angiotensin-aldosterone system and COVID-19. Mass Med Soc. 2020;382:2462–4. - PMC - PubMed